Sean D. Hood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8547075/publications.pdf

Version: 2024-02-01

76 papers 2,884 citations

293460 24 h-index 198040 52 g-index

79 all docs

79 docs citations

79 times ranked 4600 citing authors

#	Article	IF	CITATIONS
1	Visual hallucinations in psychiatry – what aren't we seeing?. Australasian Psychiatry, 2022, 30, 113-115.	0.4	3
2	N-Acetylcysteine as a novel rapidly acting anti-suicidal agent: A pilot naturalistic study in the emergency setting. PLoS ONE, 2022, 17, e0263149.	1.1	5
3	Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Australian and New Zealand Journal of Psychiatry, 2021, 55, 1127-1133.	1.3	24
4	Effects of dietary omega-3 intake on vigilant attention and resting-state functional connectivity in neurotypical children and adolescents. Nutritional Neuroscience, 2021, , 1-10.	1.5	0
5	Age-related resting-state functional connectivity of the Vigilant Attention network in children and adolescents. Brain and Cognition, 2021, 154, 105791.	0.8	1
6	Meta-analysis of the neural correlates of vigilant attention in children and adolescents. Cortex, 2020, 132, 374-385.	1.1	11
7	Exploring the relationship between auditory hallucinations, trauma and dissociation. BJPsych Open, 2020, 6, e54.	0.3	9
8	Effects of SSRI medication on heart rate and blood pressure in individuals with hypertension and depression. Clinical and Experimental Hypertension, 2019, 41, 428-433.	0.5	8
9	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14
10	Efficacy of a standardised saffron extract (affron $\hat{A}^{@}$) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study. Journal of Psychopharmacology, 2019, 33, 1415-1427.	2.0	25
11	Anxiety disorder treatment guidelines: Little by little a consensus emerges. Australian and New Zealand Journal of Psychiatry, 2019, 53, 80-81.	1.3	1
12	Using acute tryptophan depletion to investigate predictors of treatment response in adolescents with major depressive disorder: study protocol for a randomised controlled trial. Trials, 2018, 19, 434.	0.7	5
13	Use of mental-health services by Australian medical students: a cross-sectional survey. Australasian Psychiatry, 2017, 25, 407-410.	0.4	22
14	Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder. Journal of Psychopharmacology, 2017, 31, 1615-1623.	2.0	5
15	Involvement of Opioid Receptors and $\hat{i}\pm 2$ -Adrenoceptors in Inhibitory Pain Modulation Processes: A Double-Blind Placebo-Controlled Crossover Study. Journal of Pain, 2016, 17, 1164-1173.	0.7	15
16	Reduced heart rate variability in remitted bipolar disorder and recurrent depression. Australian and New Zealand Journal of Psychiatry, 2016, 50, 793-804.	1.3	29
17	Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation. Journal of Psychopharmacology, 2016, 30, 1137-1140.	2.0	5
18	Great expectations: Nutritional medicine as a mainstream in clinical psychiatry and weighing opportunities against risks. Medical Hypotheses, 2016, 88, 68-69.	0.8	2

#	Article	IF	CITATIONS
19	Diagnostic inexactitude $\hat{a}\in$ Reframing and relabelling Disruptive Mood Dysregulation Disorder for ICD-11 does not solve the problem. Medical Hypotheses, 2015, 85, 1035-1036.	0.8	3
20	Latest guidelines for the management of the anxiety disorders $\hat{a}\in$ a report from The International Anxiety Disorders Society Conference, Melbourne 2014. Australasian Psychiatry, 2015, 23, 388-391.	0.4	6
21	Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?. Journal of Psychopharmacology, 2015, 29, 1061-1069.	2.0	21
22	Why academic psychiatry is endangered. Australian and New Zealand Journal of Psychiatry, 2015, 49, 9-12.	1.3	25
23	Food and your mood: nutritional psychiatry. Lancet Psychiatry, the, 2015, 2, e19.	3.7	12
24	Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System. Current Pharmaceutical Design, 2015, 21, 3325-3342.	0.9	7
25	A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 102-111.	2.5	276
26	Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study. Journal of Affective Disorders, 2014, 167, 368-375.	2.0	146
27	Benzodiazepine dependence and its treatment with low dose flumazenil. British Journal of Clinical Pharmacology, 2014, 77, 285-294.	1.1	100
28	Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series. Journal of Psychopharmacology, 2013, 27, 222-227.	2.0	23
29	A review of lifestyle factors that contribute to important pathways associated with major depression: Diet, sleep and exercise. Journal of Affective Disorders, 2013, 148, 12-27.	2.0	463
30	Mental Health and Welfare in Australian Anaesthetists. Anaesthesia and Intensive Care, 2013, 41, 641-647.	0.2	13
31	Emotion regulation in bipolar disorder: Are emotion regulation abilities less compromised in euthymic bipolar disorder than unipolar depressive or anxiety disorders?. Open Journal of Psychiatry, 2013, 03, 1-7.	0.2	33
32	A Patient with a Pancreatic Endocrine Tumor develops Chronic Schizophrenia: Report of a Case. Journal of Clinical Case Reports, 2013, 04, .	0.0	0
33	Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review. Journal of Psychopharmacology, 2012, 26, 431-442.	2.0	13
34	Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. Journal of Psychopharmacology, 2012, 26, 1512-1524.	2.0	126
35	Central noradrenergic responsiveness to a clonidine challenge in Generalized Anxiety Disorder: a Single Photon Emission Computed Tomography study. Journal of Psychopharmacology, 2012, 26, 452-460.	2.0	9
36	Recent Developments in Anxiety Disorders. , 2012, , 184-205.		0

#	Article	IF	CITATIONS
37	Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. Journal of Psychopharmacology, 2011, 25, 78-86.	2.0	20
38	Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. Psychopharmacology, 2011, 213, 593-602.	1.5	7
39	Treatment-Refractory Generalized Anxiety Disorder. Psychiatric Annals, 2011, 41, 104-112.	0.1	3
40	Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology, 2010, 208, 223-232.	1.5	18
41	Severe Laryngeal Dystonia in a Patient Receiving Zuclopenthixol "Acuphase―and Fluoxetine. Australasian Psychiatry, 2010, 18, 174-176.	0.4	10
42	Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. Journal of Psychopharmacology, 2010, 24, 709-716.	2.0	25
43	Circadian rhythms: keeping pace with developments. Medical Journal of Australia, 2009, 191, 479-480.	0.8	1
44	The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. Journal of Psychopharmacology, 2009, 23, 401-409.	2.0	47
45	Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al Psychopharmacology, 2009, 203, 831-833.	1.5	1
46	Serotonin and Sensitivity to Trauma-Related Exposure in Selective Serotonin Reuptake Inhibitors-Recovered Posttraumatic Stress Disorder. Biological Psychiatry, 2009, 66, 17-24.	0.7	42
47	Antidepressant-induced jitteriness/anxiety syndrome: systematic review. British Journal of Psychiatry, 2009, 194, 483-490.	1.7	160
48	Women with diarrhoea-predominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. Stress, 2009, 12, 30-36.	0.8	7
49	Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?. Journal of Affective Disorders, 2008, 111, 344-350.	2.0	9
50	Serotonin 5-HT _{1A} receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry, 2008, 193, 229-234.	1.7	166
51	Potential Novel Anxiolytic Drugs. Current Pharmaceutical Design, 2008, 14, 3534-3546.	0.9	35
52	Irritable Bowel Syndrome Patients Exhibit Depressive and Anxiety Scores in the Subsyndromal Range. The Open Psychiatry Journal, 2008, 2, 12-22.	0.2	1
53	Social Anxiety Disorder - A Review of Pharmacological Treatments. Current Psychiatry Reviews, 2007, 3, 95-122.	0.9	6
54	Development and validation of the Generalized Anxiety Disorder Inventory (GADI). Journal of Psychopharmacology, 2007, 21, 145-152.	2.0	24

#	Article	IF	Citations
55	The Hurricane Choir: Remote Mental Health Monitoring of Participants in a Community-based Intervention in the post-Katrina Period. Journal of Health Care for the Poor and Underserved, 2007, 18, 356-361.	0.4	7
56	Generalized anxiety disorder: A comorbid disease. European Neuropsychopharmacology, 2006, 16, S109-S118.	0.3	72
57	Depleting Serotonin Enhances Both Cardiovascular and Psychological Stress Reactivity in Recovered Patients With Anxiety Disorders. Journal of Clinical Psychopharmacology, 2006, 26, 414-418.	0.7	48
58	Serotonin regulation of the human stress response. Psychoneuroendocrinology, 2006, 31, 1087-1097.	1.3	44
59	Recent Developments in Anxiety Disorders. Recent Patents on CNS Drug Discovery, 2006, 1, 289-298.	0.9	7
60	Acute Tryptophan Depletion Alters Gastrointestinal and Anxiety Symptoms in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 2582-2587.	0.2	33
61	Dopamine and social anxiety disorder. Revista Brasileira De Psiquiatria, 2006, 28, 263-264.	0.9	14
62	Dopamine and social anxiety disorder . Revista Brasileira De Psiquiatria, 2006, 28, .	0.9	0
63	Acute Tryptophan Depletion. Part I: Rationale and Methodology. Australian and New Zealand Journal of Psychiatry, 2005, 39, 558-564.	1.3	114
64	Acute Tryptophan Depletion. Part II: Clinical Effects and Implications. Australian and New Zealand Journal of Psychiatry, 2005, 39, 565-574.	1.3	93
65	Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biological Psychiatry, 2004, 56, 503-509.	0.7	84
66	Emergency department mental health triage consultancy service: an evaluation of the first year of the service. International Emergency Nursing, 2004, 12, 31-38.	0.7	50
67	Emergency department mental health triage consultancy service: a qualitative evaluation. International Emergency Nursing, 2003, 11, 158-165.	0.7	24
68	New directions in the treatment of anxiety disorders. Expert Opinion on Therapeutic Patents, 2003, 13, 401-423.	2.4	6
69	Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. Journal of Psychopharmacology, 2002, 16, 5-14.	2.0	87
70	Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology, 2002, 27, 715-729.	1.3	92
71	Obsessive–Compulsive Disorder: Treatment and Treatment Resistance. Australasian Psychiatry, 2001, 9, 118-127.	0.4	12
72	Social phobia: illness or illusion?. Acta Psychiatrica Scandinavica, 2001, 103, 241-243.	2.2	6

SEAN D. HOOD

#	Article	IF	CITATION
73	Arthritis and Serotonergic Antidepressants. Journal of Clinical Psychopharmacology, 2001, 21, 458-461.	0.7	9
74	Agents in Development for Anxiety Disorders. CNS Drugs, 2000, 13, 421-431.	2.7	16
75	Acute Tryptophan Depletion. Part I: Rationale and Methodology. , 0, .		12
76	Acute Tryptophan Depletion. Part II: Clinical Effects and Implications. , 0, .		8